Infinity Pharmaceuticals is part of the healthcare sector and trades as part of the biotechnology industry. The company CEO is Adelene Q. Perkins. Infinity Pharmaceuticals Inc is a biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. It is focused on advancing IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate.
Previous Intraday Performance:
The INFI shares had a previous change of -1.81% which opened at 1.65 and closed at 1.63. It moved to an intraday high of 1.66 and a low of 1.61.
Over the last five trading days, INFI shares returned -6.86% and in the past 30 trading days it returned -4.68%. Over three months, it changed 23.48%. In one year it has changed -26.24% and within that year its 52-week high was 2.92 and its 52-week low was 1.00. INFI stock is 63.00% above its 52 Week Low.
Our calculations result in a 200 day moving average of 1.79 and a 50 day moving average of 1.63. Right now, INFI stock is trading -8.75% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.
The company has a market cap of $92.8m with 56.9m shares outstanding and a float of 54.1m shares. Trading volume was 80,953 shares and has experienced an average volume of 256,710 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
The last annual reported EPS for Infinity Pharmaceuticals was -0.21 which ended on 31st of December 2018. Based on 4 analyst estimates, the consensus EPS for the next quarter is -0.08.
Base on our calculations, the intrinsic value per share is 67.62, which means it might be undervalued and has a margin of safety of 97.59%
The next earnings report will be: 05-07-2019
The long-term trend of the EPS is an important number as it indicates the present value of Infinity Pharmaceuticals; it is typically displayed as a percentage and called the EPS growth rate, which at this time is hard to estimate, but revenue growth has been 236.10% over the last twelve months.
Indicators Also to Watch:
Based on the latest filings, there is 60.80% of institutional ownership.
I calculated the beta to be 2.17
SeekingAlpha: Landmark Bancorp reports Q4 results
Based on last reported financials, the company’s return on equity is -22.93%, return on assets is -19.23%, profit margin is -11.04%, price-to-sales is 4.27 and price-to-book is 1.80.
Company Score Card:
Results are out of six:
5 : Growth Expectations Result
6 : Financial Safety Result
0 : Past Performance Result
3 : Valuation Result
0 : Dividend Safety Result
3 : Overall Result